person · Reporting owner

van der Kamp Hilde Johanna

Disclosed activity across 1 company

Tapewire entity: 69682
SEC CIK: 0002000565

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	January 07, 2026	January 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NewAmsterdam Pharma Co N.V.

Report date January 07, 2026 · Filed January 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,360	Reported balance After 2026-01-07 transaction · row 1 1 source row Row 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07	Direct	15,300	Reported balance After 2026-01-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

F2: Each RSU was granted on January 7, 2026 for no consideration.

F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 07, 2026 Filed Jan 9, 2026 19:34 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	15,300	$0.00 Strike: $35.45	$0.00	Disclosure SEC source: 0001193125-26-009274 · ownership.xml · derivative · entry 2 van der Kamp Hilde Johanna · CIK 0002000565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Ordinary Shares · 15,300 shares Expires 2036-01-07 F3 · derivative.exercise_date: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Read SEC document
January 07, 2026 Filed Jan 9, 2026 19:34 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	3,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-009274 · ownership.xml · nonDerivative · entry 1 van der Kamp Hilde Johanna · CIK 0002000565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document
January 07, 2025 Filed Jan 8, 2025 17:58 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	6,960	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-003556 · ownership.xml · nonDerivative · entry 1 van der Kamp Hilde Johanna · CIK 0002000565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,960 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document
January 06, 2025 Filed Jan 8, 2025 17:58 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	32,500	$0.00 Strike: $25.85	$0.00	Disclosure SEC source: 0000950170-25-003556 · ownership.xml · derivative · entry 2 van der Kamp Hilde Johanna · CIK 0002000565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Ordinary Shares · 32,500 shares Expires 2035-01-06 F3 · derivative.exercise_date: 1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date. Read SEC document
January 01, 2024 Filed Jan 3, 2024 17:19 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	10,000	$0.00 Strike: $11.17	$0.00	Disclosure SEC source: 0000950170-24-001133 · ownership.xml · derivative · entry 1 van der Kamp Hilde Johanna · CIK 0002000565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.